Pangea Pharmaceuticals Partners with Brillian Pharma to Commercialize Sdamlo™ — A First-of-Its-Kind, Novel, Alcohol-Free, Easy-to-administer Amlodipine Oral Solution
Pangea Pharmaceuticals, a U.S.-based pharmaceutical company focused on delivering differentiated, clinically relevant therapies, today announced a strategic commercial partnership with Brillian Pharma, granting Pangea exclusive U.S. commercialization rights to Sdamlo™ (Amlodipine Besylate), NDA 219531, across all approved strengths. The commercial launch and more information will be announced in Q1 2026. Amlodipine is one of the […]
